BACKGROUND: Although hematopoietic stem cell transplantation (HSCT) is the treatment of choice for childhood myelodysplastic syndrome (MDS), there is no consensus regarding patient or disease characteristics that predict outcomes. PROCEDURE: We reviewed 37 consecutive pediatric MDS patients who received myeloablative HSCT between 1990 and 2010 at a single center. RESULTS: Twenty had primary MDS and 17 had secondary MDS. Diagnostic cytogenetics included monosomy 7 (n = 21), trisomy 8 (n = 7) or normal/other (n = 8). According to the modified WHO MDS classification, thirty had refractory cytopenia and seven had refractory anemia with excess blasts. IPSS scores were: low risk (n = 1), intermediate-1 (n = 15), and intermediate-2 (n = 21). OS and DFS at 10 years in the entire cohort was 53% and 45%. Relapse at 10 years was 26% and 1 year TRM was 25%. In multivariate analysis, factors associated with improved 3 years DFS were not receiving pre-HSCT chemotherapy (RR = 0.30, 95% CI 0.10-0.88; P = 0.03) and a shorter interval (<140 days) from time of diagnosis to transplant (RR = 0.27, 95% CI 0.09-0.80; P = 0.02). Three years DFS in patients who did not receive pre-HSCT chemotherapy and those who had a shorter interval to transplant (n = 16) was 80%. CONCLUSION: These results suggest that children with MDS should be referred for allogeneic HSCT soon after diagnosis and that pre-HSCT chemotherapy does not appear to improve outcomes.
BACKGROUND: Although hematopoietic stem cell transplantation (HSCT) is the treatment of choice for childhood myelodysplastic syndrome (MDS), there is no consensus regarding patient or disease characteristics that predict outcomes. PROCEDURE: We reviewed 37 consecutive pediatric MDSpatients who received myeloablative HSCT between 1990 and 2010 at a single center. RESULTS: Twenty had primary MDS and 17 had secondary MDS. Diagnostic cytogenetics included monosomy 7 (n = 21), trisomy 8 (n = 7) or normal/other (n = 8). According to the modified WHO MDS classification, thirty had refractory cytopenia and seven had refractory anemia with excess blasts. IPSS scores were: low risk (n = 1), intermediate-1 (n = 15), and intermediate-2 (n = 21). OS and DFS at 10 years in the entire cohort was 53% and 45%. Relapse at 10 years was 26% and 1 year TRM was 25%. In multivariate analysis, factors associated with improved 3 years DFS were not receiving pre-HSCT chemotherapy (RR = 0.30, 95% CI 0.10-0.88; P = 0.03) and a shorter interval (<140 days) from time of diagnosis to transplant (RR = 0.27, 95% CI 0.09-0.80; P = 0.02). Three years DFS in patients who did not receive pre-HSCT chemotherapy and those who had a shorter interval to transplant (n = 16) was 80%. CONCLUSION: These results suggest that children with MDS should be referred for allogeneic HSCT soon after diagnosis and that pre-HSCT chemotherapy does not appear to improve outcomes.
Authors: H Sasaki; A Manabe; S Kojima; M Tsuchida; Y Hayashi; K Ikuta; I Okamura; K Koike; A Ohara; E Ishii; Y Komada; S Hibi; T Nakahata Journal: Leukemia Date: 2001-11 Impact factor: 11.528
Authors: Aaron T Gerds; Ted A Gooley; Elihu H Estey; Frederick R Appelbaum; H Joachim Deeg; Bart L Scott Journal: Biol Blood Marrow Transplant Date: 2012-01-16 Impact factor: 5.742
Authors: Margaret L MacMillan; Daniel J Weisdorf; John E Wagner; Todd E DeFor; Linda J Burns; Norma K C Ramsay; Stella M Davies; Bruce R Blazar Journal: Biol Blood Marrow Transplant Date: 2002 Impact factor: 5.742
Authors: G Tricot; R Vlietinck; M A Boogaerts; B Hendrickx; C De Wolf-Peeters; H Van den Berghe; R L Verwilghen Journal: Br J Haematol Date: 1985-05 Impact factor: 6.998
Authors: Gabriela Kardos; Irith Baumann; S Jane Passmore; Franco Locatelli; Henrik Hasle; Kirk R Schultz; Jan Starý; Annette Schmitt-Graeff; Alexandra Fischer; Jochen Harbott; Judith M Chessells; Ian Hann; Susanna Fenu; Angelo Cantú Rajnoldi; Gitte Kerndrup; Elisabeth Van Wering; Tim Rogge; Peter Nollke; Charlotte M Niemeyer Journal: Blood Date: 2003-05-22 Impact factor: 22.113
Authors: U Yusuf; H A Frangoul; T A Gooley; A E Woolfrey; P A Carpenter; R G Andrews; H J Deeg; F R Appelbaum; C Anasetti; R Storb; J E Sanders Journal: Bone Marrow Transplant Date: 2004-04 Impact factor: 5.483
Authors: Nicolas Waespe; Machiel Van Den Akker; Robert J Klaassen; Lani Lieberman; Meredith S Irwin; Salah S Ali; Mohamed Abdelhaleem; Bozana Zlateska; Mira Liebman; Michaela Cada; Tal Schechter; Yigal Dror Journal: Haematologica Date: 2016-08-18 Impact factor: 9.941